We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Next-Generation DNA Sequencer Platform Is Small and Affordable

By LabMedica International staff writers
Posted on 02 Jun 2010
A benchtop next-generation DNA sequencing platform is ideally suited for labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial-genome sequencing, metagenomic analysis, as well as novel pathogen detection.

The GS Junior System includes a suite of high-performance data analysis software, offering a solution for scientists who are less experienced in DNA sequencing technologies and bioinformatics. More...
The software package includes tools for de novo genome and transcriptome assembly and mapping, as well as amplicon variant analysis for the identification of rare variants in targeted sequencing studies.

Roche (Basel, Switzerland) announced the global launch of the GS Junior System, the company's new DNA sequencing platform. Developed by 454 Life Sciences (Branford, CT, USA), a Roche company, the system provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency, and price competitiveness, small and medium sized laboratories worldwide will have access to Roche's state-of-the-art sequencing capabilities at an affordable price.

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double-digit growth expected for the next several years.

Roche's Genome Sequencer FLX System has enabled hundreds of scientific discoveries, including the identification of novel pathogenic viruses, the analysis of ancient DNA from Neanderthal man and the wooly mammoth, and the characterization of microbial communities in the human gut.

"Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turnaround time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications,” said Daniel O'Day, COO of Roche Diagnostics (Indianapolis, IN, USA).

Roche is a leader in research-focused healthcare with combined strengths in diagnostics and pharmaceuticals. It is also a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche
454 Life Sciences
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.